Author of

• 25962

  +

  P3.08 - Oligometastatic NSCLC (Not CME Accredited Session) (ID 974)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall

  • 27558

    +

    P3.08-03 - Stereotactic Radiotherapy of Lung Cancer with Synchronous Bilateral Noduli or Oligometastatic Disease (ID 13801)

    12:00 - 13:30  |  Author(s): Olfred Hansen
    • Abstract

    Background
    

    Stereotactic radiotherapy (SBRT) is an efficient treatment for early stages of inoperable NSCLC. This retrospective study compares the outcome of patients diagnosed with either bilateral disease (BilatD) or oligometastatic disease (OligoD) prior to SBRT of the lung lesions

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    All cases of lung cancer treated with SBRT are prospectively recorded at our institution. We treated 75 patients with histological or cytological verified lung cancer 2009-2017 with IMRT or VMAT to a central dose 45-66 Gy in 3 fractions (F) for peripheral located tumors and 45 Gy-80 Gy/5-10F for centrally located tumors. BilatD was seen at the time of SBRT in 44 patients. In 35 patients, SBRT was used to treat simultaneous lesions in the two lungs, and in 9 patients SBRT was combined with surgical resection of a lesion in the other lung. OligoD was seen in 31 patients.

    4c3880bb027f159e801041b1021e88e8 Result
    

    Patient characteristics

    	Bilateral (N=44)	Oligometastatic (N=31)	p-value
    Age (yr.)	71.2 (47.3; 81.6)	67.8 (46.3; 86.3)	0.26
    Female /Male	13 /18	25 / 19	0.30
    PS 0-1	16 (52%)	13 (42%)
    PS 2	9 (21%)	34 (77%)	0.07
    PS 3	1 (2%)	2 (6%)
    FEV1% of normal	63% (29-139%)	71% (28-123%)	0.51
    Dose
    45 Gy /3F	13 (30%)	5 (16%)
    45 Gy/10F	1 (2%)	2 (7%)
    50 Gy /5F	3 (7%)	1 (3%)
    66 Gy /3F	23 (52%)	16 (52%)
    80 Gy /8F	4 (9%)	7 (23%)
    Metastatic site
    Lung		1 (3%)
    Brain		19 (61%)
    Adrenal gland		4 (13%)
    Bone		3 (10%)
    Pancreas/liver		2 (7%)
    Distant nodes		2 (7%)

    The median, 1, 2, 3, and 4 year overall survival was 65 mo., 79%, 64%, 56%, and 56% in BilatD and 12.3 mo., 55%, 34%, 29%, and 29 % in OligoD (p=.01).

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    

    SBRT used in BilatD was associated with significant better overall survival compared with patients with OligoD.

    6f8b794f3246b0c1e1780bb4d4d5dc53